Indole Derivatives as Serotonergic Agents for CNS Disorders
Summary
USPTO published Application US20260092035A1 disclosing indole derivatives of general Formula (I) as serotonergic agents useful for treating CNS disorders including psychosis and mental illnesses. Inventor Abdelmalik Slassi filed the application on December 9, 2025 (Application No. 19413522). This patent application publication represents a routine intellectual property filing with no compliance obligations or regulatory deadlines for third parties.
What changed
USPTO published patent application US20260092035A1 on April 2, 2026, disclosing novel indole derivatives of general Formula (I) as serotonergic agents for treating disorders related to serotonin receptor activation, including CNS disorders, psychosis, and mental illnesses. The application includes processes for preparation and compositions containing these compounds. Inventor Abdelmalik Slassi filed on December 9, 2025 under Application No. 19413522. CPC classifications include C07D 209/16, A61K 31/4045, and related pharmaceutical composition codes.
This patent application publication creates no compliance obligations, deadlines, or penalties for third parties. Pharmaceutical and drug manufacturers should note this application for prior art and freedom-to-operate considerations if developing serotonergic agents. No action is required unless conducting clearance analyses for CNS drug compounds.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
Application US20260092035A1 Kind: A1 Apr 02, 2026
Inventors
Abdelmalik SLASSI
Abstract
The present disclosure relates to indole derivatives of general Formula (I), to processes for their preparation, to compositions including them and to their use in activation of a serotonin receptors in a cell, as well as to treating diseases, disorders, or conditions by activation of a serotonin receptors in a cell. The diseases, disorders, or conditions include, for example, psychosis, mental illnesses, and central nervous system (CNS) disorders.
CPC Classifications
C07D 209/16 A61K 31/4045 A61K 31/4439 A61K 31/454 A61K 31/55 C07B 59/002 C07D 209/44 C07D 401/04 C07D 401/06 C07D 401/12 C07D 403/06 C07D 403/14 C07D 405/04 C07D 405/12 C07D 405/14 C07D 409/04 C07D 409/12 C07D 409/14
Filing Date
2025-12-09
Application No.
19413522
Named provisions
Related changes
Get daily alerts for ChangeBridge: Patent Apps - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: Patent Apps - Organic Chemistry (C07D) publishes new changes.